Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA ; volume:21 ; number:1 ; day:3 ; month:10 ; year:2023 ; pages:1-22 ; date:12.2023
Journal of nanobiotechnology ; 21, Heft 1 (3.10.2023), 1-22, 12.2023

Creator: Zhang, Shushan
Huang, Yongquan
Pi, Songying
Chen, Hui
Ye, Feile
Wu, Chaoqun
Li, Liujun
Ye, Qing
Lin, Yuhong
Su, Zhongzhen

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12951-023-02067-y

URN: urn:nbn:de:101:1-2024020907542287829749

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:24 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Zhang, Shushan
Huang, Yongquan
Pi, Songying
Chen, Hui
Ye, Feile
Wu, Chaoqun
Li, Liujun
Ye, Qing
Lin, Yuhong
Su, Zhongzhen
SpringerLink (Online service)

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

Related objects

Reset password